Literature DB >> 29029062

Multicentric evaluation of the impact of central tumour location when comparing rates of N1 upstaging in patients undergoing video-assisted and open surgery for clinical Stage I non-small-cell lung cancer†.

Herbert Decaluwé1, René Horsleben Petersen2, Alex Brunelli3, Cecilia Pompili3, Agathe Seguin-Givelet4, Lucile Gust5, Clemens Aigner6, Pierre-Emmanuel Falcoz7, Philippe Rinieri8, Florian Augustin9, Youri Sokolow10, Ad Verhagen11, Lieven Depypere1, Kostas Papagiannopoulos3, Dominique Gossot4, Xavier Benoit D'Journo5, Francesco Guerrera7, Jean-Marc Baste8, Thomas Schmid9, Alessia Stanzi1, Dirk Van Raemdonck1, Jeremy Bardet4, Pascal-Alexandre Thomas5, Gilbert Massard7, Steffen Fieuws12, Johnny Moons1, Christophe Dooms13, Paul De Leyn1, Henrik Jessen Hansen2.   

Abstract

OBJECTIVES: Large retrospective series have indicated lower rates of cN0 to pN1 nodal upstaging after video-assisted thoracic surgery (VATS) compared with open resections for Stage I non-small-cell lung cancer (NSCLC). The objective of our multicentre study was to investigate whether the presumed lower rate of N1 upstaging after VATS disappears after correction for central tumour location in a multivariable analysis.
METHODS: Consecutive patients operated for PET-CT based clinical Stage I NSCLC were selected from prospectively managed surgical databases in 11 European centres. Central tumour location was defined as contact with bronchovascular structures on computer tomography and/or visibility on standard bronchoscopy.
RESULTS: Eight hundred and ninety-five patients underwent pulmonary resection by VATS (n = 699, 9% conversions) or an open technique (n = 196) in 2014. Incidence of nodal pN1 and pN2 upstaging was 8% and 7% after VATS and 15% and 6% after open surgery, respectively. pN1 was found in 27% of patients with central tumours. Less central tumours were operated on by VATS compared with the open technique (12% vs 28%, P < 0.001). Logistic regression analysis showed that only tumour location had a significant impact on N1 upstaging (OR 6.2, confidence interval 3.6-10.8; P < 0.001) and that the effect of surgical technique (VATS versus open surgery) was no longer significant when accounting for tumour location.
CONCLUSIONS: A quarter of patients with central clinical Stage I NSCLC was upstaged to pN1 at resection. Central tumour location was the only independent factor associated with N1 upstaging, undermining the evidence for lower N1 upstaging after VATS resections. Studies investigating N1 upstaging after VATS compared with open surgery should be interpreted with caution due to possible selection bias, i.e. relatively more central tumours in the open group with a higher chance of N1 upstaging.
© The Author 2017. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Lymph node; N1; Non-small-cell lung cancer; Thoracoscopic; Upstaging; Video-assisted thoracic surgery

Mesh:

Year:  2018        PMID: 29029062     DOI: 10.1093/ejcts/ezx338

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  8 in total

1.  Risk of recurrence in stage I adenocarcinoma of the lung: a multi-institutional study on synergism between type of surgery and type of nodal staging.

Authors:  Francesco Guerrera; Filippo Lococo; Andrea Evangelista; Ottavio Rena; Luca Ampollini; Jacopo Vannucci; Luca Errico; Paolo Olivo Lausi; Luigi Ventura; Valentina Marchese; Massimiliano Paci; Pier Luigi Filosso; Alberto Oliaro; Caterina Casadio; Francesco Puma; Enrico Ruffini; Francesco Ardissone
Journal:  J Thorac Dis       Date:  2019-02       Impact factor: 2.895

2.  Is invasive mediastinal staging necessary in intermediate risk patients with negative PET/CT?

Authors:  Marc Boada; David Sánchez-Lorente; Alejandra Libreros; Carmen M Lucena; Ramón Marrades; Marcelo Sánchez; Pilar Paredes; Mario Serrano; Angela Guirao; Rudith Guzmán; Núria Viñolas; Francesc Casas; Carles Agustí; Laureano Molins
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

3.  Comparison of the Video-assisted Thoracoscopic Lobectomy versus Open Thoracotomy for Primary Non-Small Cell Lung Cancer: Single Cohort Study with 269 Cases.

Authors:  Volkan Erdogu; Hasan Akin; Yasar Sonmezoglu; Ali Cevat Kutluk; Celal Bugra Sezen; Mustafa Vedat Dogru; Ozkan Saydam; Muzaffer Metin
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2020-09-04

4.  The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases.

Authors:  Michelle C Salazar; Maureen E Canavan; Samantha L Walters; Sitaram Chilakamarry; Theresa Ermer; Justin D Blasberg; James B Yu; Cary P Gross; Daniel J Boffa
Journal:  JTO Clin Res Rep       Date:  2021-01-21

5.  Quantification of the spatial distribution of primary tumors in the lung to develop new prognostic biomarkers for locally advanced NSCLC.

Authors:  Diem Vuong; Marta Bogowicz; Leonard Wee; Oliver Riesterer; Eugenia Vlaskou Badra; Louisa Abigail D'Cruz; Panagiotis Balermpas; Janita E van Timmeren; Simon Burgermeister; André Dekker; Dirk De Ruysscher; Jan Unkelbach; Sandra Thierstein; Eric I Eboulet; Solange Peters; Miklos Pless; Matthias Guckenberger; Stephanie Tanadini-Lang
Journal:  Sci Rep       Date:  2021-10-22       Impact factor: 4.379

6.  Nerve at risk: anatomical variations of the left recurrent laryngeal nerve and implications for thoracic surgeons.

Authors:  Caecilia Ng; Claudia Woess; Herbert Maier; Verena-Maria Schmidt; Paolo Lucciarini; Dietmar Öfner; Walter Rabl; Florian Augustin
Journal:  Eur J Cardiothorac Surg       Date:  2020-12-01       Impact factor: 4.191

7.  Video-assisted thoracoscopic lobectomy is feasible for selected patients with clinical N2 non-small cell lung cancer.

Authors:  Jae Kwang Yun; Geun Dong Lee; Sehoon Choi; Hyeong Ryul Kim; Yong-Hee Kim; Seung-Il Park; Dong Kwan Kim
Journal:  Sci Rep       Date:  2020-09-16       Impact factor: 4.379

Review 8.  Video-assisted mediastinoscopic lymphadenectomy (VAMLA) for staging & treatment of non-small cell lung cancer (NSCLC).

Authors:  Marc Hartert; Jan Tripsky; Martin Huertgen
Journal:  Mediastinum       Date:  2020-03-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.